Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17057946 | METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS | November 2020 | October 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 17046161 | FOXM1 INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME | October 2020 | May 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17040003 | PROCESS FOR OXIDISING A SUBSTRATE | September 2020 | January 2025 | Abandon | 52 | 1 | 1 | No | No |
| 16982395 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | September 2020 | June 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16975134 | Heterobicyclic Carboxylic Acids and Salts Thereof | August 2020 | December 2024 | Allow | 52 | 2 | 1 | No | No |
| 16819829 | ANTIDIABETIC COMPOUNDS | March 2020 | April 2020 | Allow | 1 | 0 | 0 | No | No |
| 16690556 | ANTIDIABETIC COMPOUNDS | November 2019 | March 2020 | Allow | 4 | 2 | 0 | No | No |
| 16532118 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | August 2019 | December 2019 | Allow | 5 | 0 | 0 | No | No |
| 16344340 | CRYSTALLINE FORM OF (R)-4-HYDROXY-2-OXO-1-PYRROLIDINEACETAMIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2019 | December 2019 | Allow | 8 | 0 | 0 | No | No |
| 16280534 | Antifungal Compound Process | February 2019 | May 2019 | Allow | 2 | 1 | 0 | No | No |
| 16260864 | COMPOUNDS FOR TREATING PARASITIC INFECTIONS | January 2019 | January 2020 | Allow | 12 | 0 | 1 | No | No |
| 16244950 | NOVEL CHIRAL DIHYDROBENZOOXAPHOSPHOLE LIGANDS AND SYNTHESIS THEREOF | January 2019 | September 2019 | Allow | 8 | 0 | 1 | No | No |
| 16166582 | METHODS FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVES | October 2018 | December 2019 | Allow | 14 | 2 | 0 | No | No |
| 16156718 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | October 2018 | August 2019 | Allow | 10 | 0 | 0 | No | No |
| 16114714 | PROCESS FOR THE PREPARATION OF ACLIDINIUM BROMIDE | August 2018 | October 2019 | Allow | 14 | 0 | 1 | No | No |
| 16113533 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | August 2018 | February 2019 | Allow | 6 | 1 | 0 | No | No |
| 16107220 | COMPOUNDS AND THEIR METHODS OF USE | August 2018 | February 2020 | Allow | 18 | 1 | 1 | No | No |
| 16060486 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | June 2018 | June 2019 | Allow | 12 | 0 | 0 | No | No |
| 15768953 | KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF | April 2018 | March 2020 | Allow | 23 | 2 | 1 | Yes | No |
| 15934246 | TREATMENT METHOD UTILIZING PYRROLIDINE-2, 5-DIONE DERIVATIVES AS IDO1 INHIBITORS | March 2018 | April 2019 | Allow | 13 | 1 | 0 | No | No |
| 15919460 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | March 2018 | February 2019 | Allow | 11 | 0 | 0 | No | No |
| 15886766 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | February 2018 | October 2018 | Allow | 9 | 0 | 1 | No | No |
| 15580137 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | December 2017 | February 2019 | Allow | 14 | 0 | 1 | No | No |
| 15832799 | NOVEL CHIRAL DIHYDROBENZOOXAPHOSPHOLE LIGANDS AND SYNTHESIS THEREOF | December 2017 | October 2018 | Allow | 10 | 0 | 1 | No | No |
| 15801201 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | November 2017 | July 2019 | Allow | 20 | 2 | 0 | No | No |
| 15783783 | NOVEL COUMARINYL-THIAZOLE-SULFONYL CONJUGATE AND PREPARATION THEREOF | October 2017 | August 2018 | Allow | 10 | 1 | 0 | No | No |
| 15553622 | Heterocyclic Compounds and Methods of Use | August 2017 | September 2018 | Allow | 12 | 1 | 1 | Yes | No |
| 15552997 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | August 2017 | June 2018 | Allow | 10 | 1 | 0 | No | No |
| 15551132 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | August 2017 | June 2018 | Allow | 10 | 0 | 0 | Yes | No |
| 15546348 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | July 2017 | March 2019 | Allow | 20 | 2 | 1 | No | No |
| 15612240 | HEPATITIS B ANTIVIRAL AGENTS | June 2017 | September 2018 | Allow | 15 | 1 | 1 | Yes | No |
| 15527909 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | May 2017 | March 2019 | Allow | 22 | 3 | 0 | No | No |
| 15474193 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | March 2017 | January 2018 | Allow | 9 | 2 | 0 | Yes | No |
| 15512501 | METHODS FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVES | March 2017 | June 2018 | Allow | 15 | 1 | 1 | No | No |
| 15328341 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | January 2017 | February 2018 | Allow | 13 | 0 | 1 | Yes | No |
| 15305808 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASES POLYPEPTIDES | October 2016 | May 2017 | Allow | 7 | 0 | 0 | Yes | No |
| 15228681 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | August 2016 | December 2017 | Allow | 16 | 1 | 0 | No | No |
| 15101380 | N-CYCLOALKYL-N-{[2-(1-SUBSTITUTEDCYCLOALKYL)PHENYL]METHYLENE}-(THIO)CARBOXAMIDE DERIVATIVES | June 2016 | April 2018 | Allow | 23 | 3 | 0 | Yes | No |
| 15086120 | COMPOUNDS | March 2016 | July 2017 | Allow | 16 | 1 | 0 | Yes | No |
| 14783207 | NOVEL TRIAZOLINTHIONE DERIVATIVES | October 2015 | November 2016 | Allow | 14 | 0 | 1 | Yes | No |
| 14782889 | METHOD FOR OBTAINING SOLUTIONS OF OTA IN A CONCENTRATED SULFURIC ACID MEDIUM; SAID SOLUTIONS; AND METHOD FOR PREPARING ONTA | October 2015 | February 2017 | Allow | 16 | 0 | 1 | No | No |
| 14777630 | SMALL MOLECULE INHIBITORS OF PI3-KINASE SIGNALING | September 2015 | March 2017 | Allow | 18 | 1 | 0 | No | No |
| 14777481 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | September 2015 | November 2016 | Allow | 14 | 1 | 0 | Yes | No |
| 14766646 | ANTIVIRAL COMPOUNDS | August 2015 | October 2017 | Allow | 26 | 4 | 0 | No | No |
| 14649146 | 3,3'-DINITRO-5,5'-BIS-TRIAZOLE-1,1'-DIOL | June 2015 | August 2016 | Allow | 14 | 0 | 0 | No | No |
| 14690537 | PROCESSES FOR THE PREPARATION OF 3,5-DISUBSTITUTED-1,2,4-OXADIAZOLES | April 2015 | October 2015 | Allow | 6 | 0 | 0 | No | No |
| 14436035 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | April 2015 | June 2016 | Allow | 14 | 0 | 0 | No | No |
| 14639603 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | March 2015 | March 2016 | Allow | 13 | 1 | 0 | Yes | No |
| 14409806 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | December 2014 | December 2015 | Allow | 12 | 0 | 0 | No | No |
| 14517956 | ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING | October 2014 | July 2015 | Allow | 9 | 0 | 0 | Yes | No |
| 14489231 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | September 2014 | September 2016 | Allow | 24 | 1 | 1 | No | No |
| 14384840 | PESTICIDAL ARYLPYRROLIDINES | September 2014 | August 2015 | Allow | 12 | 0 | 1 | Yes | No |
| 14473720 | PROCESS FOR PRODUCING ISOXAZOLINE DERIVATIVES | August 2014 | February 2016 | Allow | 17 | 1 | 0 | No | No |
| 14377839 | SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS | August 2014 | November 2015 | Allow | 15 | 0 | 1 | Yes | No |
| 14376931 | PROCESS FOR THE PREPARATION OF N-HYDROXY-1-(1-ALKYL-1H-TETRAZOL-5-YL)-1-PHENYLMETHANIMINE DERIVATIVES | August 2014 | August 2015 | Allow | 12 | 0 | 0 | No | No |
| 14338357 | PHASE-TRANSFER CATALYSED FORMATION OF N-(SUBSTITUTED PHENYL) SULFONAMIDES IN WATER | July 2014 | July 2016 | Allow | 24 | 2 | 0 | No | No |
| 14338829 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | July 2014 | February 2016 | Allow | 19 | 0 | 1 | No | No |
| 14372893 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | July 2014 | January 2016 | Allow | 18 | 0 | 1 | No | No |
| 14307272 | DERIVATIVES OF 1-(SUBSTITUTED SULFONYL)-2-AMINOIMIDAZOLINE AS ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | June 2014 | November 2014 | Allow | 5 | 1 | 0 | No | No |
| 14357085 | METHOD FOR PRODUCING 4-BENZYL-1-METHYL-6-OXABICYCLO[3,2,0]HEPTANE DERIVATIVE | May 2014 | October 2014 | Allow | 5 | 0 | 0 | Yes | No |
| 14357058 | METHOD FOR MANUFACTURING 4-BENZYL-1-METHYL-6-OXABICYCLO[3,2,0]HEPTANE DERIVATIVE AND METHOD FOR MANUFACTURING AZOLE DERIVATIVE | May 2014 | March 2015 | Allow | 10 | 1 | 0 | No | No |
| 14237117 | 1,2,4-TRIAZOLYL-SUBSTITUTED KETOENOLS | May 2014 | September 2015 | Allow | 19 | 1 | 1 | Yes | No |
| 14356232 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH BRAF INHIBITORS | May 2014 | March 2016 | Allow | 23 | 2 | 0 | No | No |
| 14264574 | OPTICALLY ACTIVE FLUCONAZOLE ANALOGUES CONTAINING THIOPHENES AS ANTIFUNGAL AGENTS | April 2014 | June 2016 | Allow | 25 | 3 | 0 | Yes | No |
| 14249226 | DERIVATIVES OF 1-(SUBSTITUTED SULFONYL)-2-AMINOIMIDAZOLINE AS ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | April 2014 | March 2015 | Allow | 11 | 2 | 0 | Yes | No |
| 14220650 | COMPOUNDS | March 2014 | July 2015 | Allow | 16 | 0 | 1 | No | No |
| 14213240 | AZOLE DERIVATIVES, METHODS FOR PRODUCING THE SAME, INTERMEDIATE THEREOF, AGRO-HORTICULTURAL AGENTS | March 2014 | June 2015 | Allow | 15 | 0 | 0 | Yes | No |
| 14213043 | AZOLE DERIVATIVES, METHODS FOR PRODUCING THE SAME, INTERMEDIATE THEREOF, AGRO-HORTICULTURAL AGENTS | March 2014 | May 2015 | Allow | 14 | 0 | 0 | Yes | No |
| 14232434 | FUNGICIDAL ALKYL- AND ARYL-SUBSTITUTED 2-[2-CHLORO-4-(DIHALO-PHENOXY)-PHENYL]-1-[1,2,4]TRIAZOL-1-YL-ETHANOL COMPOUNDS | January 2014 | May 2015 | Allow | 16 | 1 | 1 | No | No |
| 14124546 | AZOLE DERIVATIVE, METHOD FOR PRODUCING SAME, INTERMEDIATE COMPOUND, AND AGRICULTURAL OR HORTICULTURAL CHEMICAL AGENT AND INDUSTRIAL MATERIAL PROTECTING AGENT | January 2014 | January 2015 | Allow | 13 | 0 | 1 | Yes | No |
| 14110315 | G-QUADRUPLEX STABILISING AGENT | December 2013 | May 2015 | Allow | 19 | 0 | 1 | Yes | No |
| 14123409 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | December 2013 | March 2015 | Allow | 15 | 0 | 0 | Yes | No |
| 14074023 | ARYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | November 2013 | March 2014 | Allow | 4 | 0 | 0 | Yes | No |
| 13988361 | PROCESS FOR THE PREPARATION OF DEFERASIROX | October 2013 | January 2015 | Allow | 20 | 0 | 1 | No | No |
| 14055442 | CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS | October 2013 | March 2016 | Allow | 29 | 1 | 1 | No | No |
| 14009452 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | October 2013 | April 2015 | Allow | 18 | 1 | 1 | Yes | No |
| 14041539 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | September 2013 | January 2014 | Allow | 4 | 1 | 0 | Yes | No |
| 14035644 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | September 2013 | September 2014 | Allow | 12 | 0 | 0 | Yes | No |
| 13985527 | 1,2,3-TRIAZOLE CONTAINING ARTEMISININ COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | August 2013 | December 2014 | Allow | 16 | 1 | 0 | No | No |
| 13979577 | POLYMORPHISM IN 5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-CYANO-4-TRIFLUORO METHYL SULFINYL PYRAZOLE | July 2013 | October 2015 | Allow | 27 | 1 | 1 | No | No |
| 13936553 | METHOD FOR PRODUCING IMATINIB BASE | July 2013 | March 2015 | Allow | 21 | 2 | 0 | No | No |
| 13933616 | PROCESSES FOR THE PREPARATION OF 3,5-DISUBSTITUTED-1,2,4-OXADIAZOLES | July 2013 | February 2015 | Allow | 19 | 1 | 0 | No | No |
| 13872860 | Process for the synthesis of halogenated cyclic compounds | April 2013 | November 2014 | Allow | 19 | 1 | 0 | No | No |
| 13697802 | PREPARATION OF POSACONAZOLE INTERMEDIATES | March 2013 | February 2015 | Allow | 27 | 1 | 1 | Yes | No |
| 13818660 | PROCESS FOR PREPARATION OF RUFINAMIDE | February 2013 | July 2014 | Allow | 16 | 0 | 1 | Yes | No |
| 13816292 | PROCESS FOR THE PREPARATION OF TAPENTADOL | February 2013 | May 2014 | Allow | 15 | 1 | 1 | Yes | No |
| 13813688 | PENTAERYTHRITOL TETRAESTER | February 2013 | October 2013 | Allow | 8 | 0 | 0 | No | No |
| 13812117 | BETA-KETOCARBONYLQUAT COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | January 2013 | January 2014 | Allow | 11 | 1 | 1 | No | No |
| 13705506 | OPTICALLY ACTIVE AMMONIUM SALT COMPOUND, PRODUCTION INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF | December 2012 | November 2014 | Allow | 23 | 1 | 1 | No | No |
| 13663741 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | October 2012 | November 2014 | Allow | 25 | 1 | 1 | Yes | No |
| 13634263 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | September 2012 | May 2014 | Allow | 20 | 1 | 1 | Yes | No |
| 13624107 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | September 2012 | October 2013 | Allow | 12 | 1 | 1 | No | No |
| 13509125 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION | July 2012 | December 2013 | Allow | 19 | 1 | 1 | Yes | No |
| 13555804 | COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES | July 2012 | March 2014 | Allow | 19 | 0 | 0 | Yes | No |
| 13508269 | AZOLE DERIVATIVES, METHODS FOR PRODUCING THE SAME, INTERMEDIATE THEREOF, AGRO-HORTICULTURAL AGENTS | May 2012 | December 2013 | Allow | 19 | 1 | 0 | Yes | No |
| 13393374 | OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | May 2012 | August 2013 | Allow | 18 | 1 | 1 | Yes | No |
| 13392583 | Polymorphic Forms of Manidipine | May 2012 | February 2015 | Allow | 35 | 1 | 1 | Yes | No |
| 13502465 | PI3 KINASE INHIBITORS | April 2012 | August 2013 | Allow | 16 | 1 | 0 | Yes | No |
| 13353392 | INHIBITORS OF AUTOTAXIN | January 2012 | October 2013 | Allow | 21 | 2 | 1 | No | No |
| 13257887 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | December 2011 | September 2013 | Allow | 24 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHENG, KAREN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHENG, KAREN works in Art Unit 1623 and has examined 124 patent applications in our dataset. With an allowance rate of 99.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 16 months.
Examiner CHENG, KAREN's allowance rate of 99.2% places them in the 92% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHENG, KAREN receive 1.03 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHENG, KAREN is 16 months. This places the examiner in the 97% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +1.6% benefit to allowance rate for applications examined by CHENG, KAREN. This interview benefit is in the 22% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 35.4% of applications are subsequently allowed. This success rate is in the 80% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 58.8% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 68.8% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.